Access Bio Inc Asset Resilience Ratio
Access Bio Inc asset resilience ratio. Access Bio Inc (950130) has an Asset Resilience Ratio of 12.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 950130 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Access Bio Inc (2012–2024)
Asset resilience ratio of Access Bio Inc from 2012 to 2024. This chart shows how Access Bio Inc's Asset Resilience Ratio has changed over time. See 950130 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Access Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Access Bio Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩83.51 Billion | 12.52% |
| Total Liquid Assets | ₩83.51 Billion | 12.52% |
Asset Resilience Insights
- Moderate Liquidity: Access Bio Inc has 12.52% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Access Bio Inc Industry Peers by Asset Resilience Ratio
Compare Access Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Voxel S.A.
WAR:VOX |
Diagnostics & Research | 0.32% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
BioPorto
CO:BIOPOR |
Diagnostics & Research | 55.77% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
Access Bio Inc Asset Resilience Ratio by Year (2012–2024)
Access Bio Inc asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for Access Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.20% | ₩76.60 Million ≈ $51.91K |
₩503.98 Million ≈ $341.54K |
+5.16pp |
| 2023-12-31 | 10.04% | ₩69.37 Billion ≈ $47.01 Million |
₩691.14 Billion ≈ $468.37 Million |
-46.28pp |
| 2022-12-31 | 56.32% | ₩393.51 Million ≈ $266.68K |
₩698.71 Million ≈ $473.51K |
+11.00pp |
| 2021-12-31 | 45.32% | ₩168.98 Million ≈ $114.52K |
₩372.85 Million ≈ $252.67K |
+15.74pp |
| 2020-12-31 | 29.58% | ₩46.27 Million ≈ $31.36K |
₩156.42 Million ≈ $106.00K |
+18.09pp |
| 2019-12-31 | 11.49% | ₩6.92 Million ≈ $4.69K |
₩60.23 Million ≈ $40.81K |
+0.77pp |
| 2018-12-31 | 10.72% | ₩9.09 Million ≈ $6.16K |
₩84.82 Million ≈ $57.48K |
+3.38pp |
| 2017-12-31 | 7.34% | ₩6.39 Million ≈ $4.33K |
₩87.15 Million ≈ $59.06K |
-20.09pp |
| 2016-12-31 | 27.43% | ₩25.02 Million ≈ $16.95K |
₩91.22 Million ≈ $61.82K |
+25.47pp |
| 2015-12-31 | 1.96% | ₩1.59 Billion ≈ $1.08 Million |
₩81.12 Billion ≈ $54.97 Million |
-21.63pp |
| 2014-12-31 | 23.59% | ₩18.62 Billion ≈ $12.62 Million |
₩78.93 Billion ≈ $53.49 Million |
+21.62pp |
| 2013-12-31 | 1.97% | ₩1.17 Billion ≈ $791.54K |
₩59.19 Billion ≈ $40.11 Million |
+1.22pp |
| 2012-12-31 | 0.75% | ₩219.00 Million ≈ $148.41K |
₩29.09 Billion ≈ $19.71 Million |
-- |
About Access Bio Inc
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities wi… Read more